NCT01948024View on ClinicalTrials.gov

Bio-equivalence Study Between SAPHRIS and Asenapine

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
SchizophreniaBipolar Disorder
Interventions
DRUG

SAPHRIS

10 mg BID sublingual tablet

DRUG

Asenapine

10 mg BID sublingual tablet

Trial Locations (7)

28204

New Hope Clinical Research, Charlotte

30308

Atlanta Center for Medical Research, Atlanta

33136

Advanced Pharma CR, LLC, Miami

34748

Compass Research North, LLC, Leesburg

72211

Woodland International Research Group, Inc., Little Rock

92280

Clinical Innovations, Inc, Costa Mesa

92845

Collaborative Neuroscience Network, LLC, Garden Grove

All Listed Sponsors
collaborator

bioRASI, LLC

INDUSTRY

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT01948024 - Bio-equivalence Study Between SAPHRIS and Asenapine | Biotech Hunter | Biotech Hunter